Freenome

Freenome is a biotechnology company that develops blood-based tests for early cancer detection. The company utilizes artificial intelligence and multiomics technology in its operations. Freenome develops and provides blood-based tests specifically for early cancer detection, including a test designed for colorectal cancer screening. Its multiomics platform integrates computational biology, machine learning, and various data types to identify biomarkers and detect different types of cancers. Freenome conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies. These studies are aimed at validating and expanding its cancer detection tests to cover multiple cancer types. The company collaborates with healthcare organizations and partners to advance its clinical studies and enhance its product portfolio. This portfolio includes an autoantibody platform that incorporates additional biomarkers. Freenome also provides patient stratification and monitoring solutions, leveraging its multiomics technology. The company was founded in 2014 and is headquartered in Brisbane, California.